Inflammation-Based Index and Ga-68-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with Y-90-DOTATOC

Elin Pauwels, Sofie Van Binnebeek, Vincent Vandecaveye, Kristof Baete, Hubert Vanbilloen, Michel Koole, Felix M. Mottaghy, Karin Haustermans, Paul M. Clement, Kristiaan Nackaerts, Eric Van Cutsem, Chris Verslype, Christophe M. Deroose*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1014-1020
Number of pages7
JournalJournal of Nuclear Medicine
Volume61
Issue number7
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • PRRT
  • Ga-68-DOTATOC
  • Y-90-DOTATOC
  • neuroendocrine tumors
  • PET
  • RADIOLABELED SOMATOSTATIN ANALOG
  • RECEPTOR RADIONUCLIDE THERAPY
  • OCTREOTATE
  • TOXICITY
  • SUV

Cite this

Pauwels, E., Binnebeek, S. V., Vandecaveye, V., Baete, K., Vanbilloen, H., Koole, M., Mottaghy, F. M., Haustermans, K., Clement, P. M., Nackaerts, K., Cutsem, E. V., Verslype, C., & Deroose, C. M. (2020). Inflammation-Based Index and Ga-68-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with Y-90-DOTATOC. Journal of Nuclear Medicine, 61(7), 1014-1020. https://doi.org/10.2967/jnumed.119.236935